Home / Lung Cancer / Clinical Trials / Adjuvant Trials

Adjuvant Trials

A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC) (LIBRETTO-432)
 

            ClinicalTrials.gov Identifier                         NCT04819100       
 
This study is currently recruiting. 

 

The reason for this study is to see if the study drug, selpercatinib, compared to placebo is effective and safe in delaying cancer return in participants with early-stage non-small cell lung cancer (NSCLC), who have already had surgery or radiation. Participants who are assigned to placebo and stop the study drug because their disease comes back or gets worse have the option to potentially crossover to selpercatinib. Participation could last up to three years.

Ontario
Princess Margaret Hospital, Toronto
Principal Investigator: Penelope Bradbury
 
            ClinicalTrials.gov Identifier                         NCT05120349       
 
This study is currently recruiting. 
 
This is a global study to assess the effects of osimertinib in participants with EGFRm stage IA2-IA3 non-small cell lung cancer following complete tumour resection.
 
British Columbia
Vancouver
 
Ontario
Toronto
 
Quebec
Montreal
 
 
                     ClinicalTrials.gov Identifier                                NCT04966663    

This study is currently recruiting.
 
This is a study to look at whether the presence of circulating tumour DNA (ctDNA) in the blood can help to predict whether giving adjuvant treatment after surgery can decrease the chance of the cancer coming back in people with lung cancer.

Ontario
Princess Margaret Cancer Centre, Toronto, ON
 

Using ctDNA to Detect Minimal Residual Disease After Lung Cancer Resection

           ClinicalTrials.gov Identifier:                   NCT05254782     

This study is currently recruiting participants.
 

ctDNALung-Detect is an investigator-initiated single arm, multi-institution study designed to assess the ctDNA detection rate and its association with Relapse Free Survival (RFS) in operable stage T1-T4 (T3,T4 multifocal) N0M0 non-small cell lung cancer (NSCLC) patients.    

Ontario
Michael Garron Hospital, Toronto
Contact: Najib Safieddine, MD 
    
St. Joseph's Health Centre, Toronto
Contact: Michael Ko, MD, PhD         

University Health Network, Toronto
Contact: Natasha Leighl, MD  
            ClinicalTrials.gov Identifier                         NCT02273375        
 
This study is currently active, not recruiting. 
 
The purpose of this study is to find out whether it is better to receive a new drug, MEDI4736, or better to receive no further treatment after surgery (and possibly chemotherapy) for lung cancer.         
 
Alberta
Cross Cancer Institute, Edmonton
Tom Baker Cancer Centre, Calgary

Newfoundland & Labrador
Dr H Bliss Murphy Cancer Centre, St John's
 
Nova Scotia
QE II Health Sciences Centre, Halifax

Ontario
Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton
Cancer Centre of Southeastern Ontario at Kingston, Kingston
Lakeridge Health, Oshawa
Ottawa Hospital Research Institute, Ottawa
Algoma District Cancer Program, Sault Ste Marie
Niagara Health System, St Catherines
Health Sciences North, Sudbury
Thunder Bay Regional Health Science Centre, Thunder Bay 
Mount Sinai Hospital, Toronto, ON
Princess Margaret Hospital, University Health Network, Toronto
 
Quebec
McGill University Oncology Department, Montreal

Saskatchewan
Allan Blair  Cancer Centre, Regina
Saskatoon Cancer Centre, Saskatoon 
 
AZD9291 Versus Placebo in Patients with Stage IB-IIIA Non-small Cell Lung Carcinoma, Folowing Complete Tumour Resection With or Without Adjuvant Chemotherapy (ADAURA) 
 
            ClinicalTrials.gov Identifier                         NCT02511106         

This study is active but not currently recruiting. 

A Phase III, Double-blind, Randomized, Placebo-controlled Multi-centre, Study to Assess the Efficacy and Safety of AZD9291 Versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy (ADAURA)

New Brunswick
Moncton

Ontario
Brampton